MAPT and Alzheimer disease: Additionally, molecular imaging with positron emission tomography (PET) of amyloid, tau, and glycolytic metabolism5 have demonstrated a clinical utility for neuroimaging in predictive/clinical diagnosis and care for AD and related dementias.